suspicious for malignancy (sfm) milan system for reporting...
TRANSCRIPT
Dr Ashish Chandra MD FRCPath DipRCPath (Cytol)
Guy’s & St Thomas’ NHSfT, London, UK
Suspicious for Malignancy (SfM)Milan system for reporting salivary gland
cytopathology
Malignant
Confident diagnosis of malignancy of an identified tumor type, supported by ancillary tests if necessary
Requires adequate diagnostic material and presence of diagnostic criteria
Allows definitive clinical management and the diagnosis can stand up to scrutiny and be confirmed on subsequent histology
SfM-definition and reasons
A salivary gland FNA is classified as SM when some, but not all the criteria for a specific diagnosis of malignancy are present, and yet the overall cytologic features are suggestive of malignancy
Markedly atypical cells with poor smear preparation, poor cell preservation, fixation artifact, or obscuring inflammation and blood
Presence of limited cytologic features of a specific malignant lesion (eg. adenoid cystic carcinoma, mucoepidermoid carcinoma, and acinic cell carcinoma) in an otherwise sparsely cellular aspirate
Presence of markedly atypical and/or suspicious cytologic features in a subset of cells but admixed with features of a benign salivary gland lesion
SfM
• Markedly atypical cells suspicious for high-grade carcinoma, but with obscuring blood limiting the assessment (smear, Romanowsky stain)
SfM
• The smear shows rare markedly atypical cells suggestive of carcinoma, but the classification is limited by scant cellularity (smear, Papanicolaou stain)
SfM
• The smear shows a group of epithelial cells suggestive of acinic cell carcinoma, but hypocellularity and background blood in the absence of ancillary studies limits the evaluation (smear, Papanicolaou stain)
SfM
• This smear is composed of basaloid cells and abundant matrix spheres with a pattern suspicious for adenoid cystic carcinoma (smear, Papanicolaou stain)
SfM
• The smear consists of epithelial cells with epidermoid features, suggestive of mucoepidermoid carcinoma (smear, Romanowsky stain)
SfM
• This aspirate shows a monotonous population of intermediate- size lymphocytes that, based upon cytomorphology alone, are highly suspicious for lymphoma
• Additional ancillary studies including immunophenotyping are needed for classification (smear, Papanicolaou stain)
Case 1
Male, 82 years
Presented with sudden appearance of a painless nodule
in the parotid
USG FNA performed
Scanned slide discussion
SfM onsite evaluation: low cellularity
Cell type
• Glandular
• Squamous
• Oncocytic
• Clear cell
• Basaloid
• Plasmacytoid
• Spindled
Stroma
• Fibrillary
• Globular
• None
Background
• Mucin
• Necrosis
• Lymphocytic
• Other (inflammation etc)
SfM onsite evaluation
Cell type
• Glandular
• Squamous
• Oncocytic
• Clear cell
• Basaloid
• Plasmacytoid
• Spindled
Stroma
• Fibrillary
• Globular
• None
Background
• Mucin
• Necrosis
• Lymphocytic
• Other (inflammation etc)
SfM diagnostic algorithm
Glandular cell type
Low grade cytology: acinic cell carcinoma, secretory carcinoma, polymorphous adenocarcinoma, metastatic carcinoma
High grade cytology: salivary duct carcinoma, metastatic carcinoma
SfM diagnostic algorithm for this case
Glandular cell type
Salivary duct carcinoma
Metastatic carcinoma
High grade + Necrosis
TTF1, PSA, PRAP, AR, GCDFP1
PSMA+
Findings on cell block
• TTF1, PSA,PRAP, AR, GCDFP1 –
• PSMA+
• Metastatic prostatic adenocarcinoma
• Fukasawa Y. · Honda T. · Natsume M. et al. A Case of Advanced Submandibular Gland Cancer in Which Increased Prostate-Specific Antigen and Multiple Bone Metastases Wrongly Suggested Concurrent Prostate Cancer.
Salivary duct carcinoma
Histological findings of salivary duct carcinoma
• a H&E staining of submaxillary gland duct carcinoma (×100). Cancer cells grow to solidity and invade striated muscles (arrow).
• b Circular or irregular nucleus with clear nucleoli, and cells with abundant basic cell grow to solidity. These are rich in color, such as large nuclei and polyhedral cells, and oncocyte-like cells also mix (×400).
• c Immunostaining for PSA shows the focal presence of PSA-positive cells (×400).
Salivary duct carcinoma vs metastatic prostate carcinoma
Specific similarities are that (1) HE staining of the ductal lumens shows the characteristic findings of both comedonecrosis and cribriform pattern
(2) tumor cells do not show a keratinizing tendency or intercellular bridges;
(3) mucus staining (with mucicarmine alcian blue) shows no evidence of mucus production in the cytoplasm.
Barnes L, Eveson JW: World Health Organization Classification of Tumors. Pathology and Genetics of Head and Neck Tumors. Lyon, IARC Press, 2005, pp 236–243.
Metastatic prostate carcinoma to salivary glands
More commonly prostate cancer metastasis can occur in-
Bone, Lymph node, Lung, Liver, Brain
Rare locations of prostate cancer metastasis include-
Adrenal gland, Breast, Eye, Kidney, Muscle, Pancreas, Salivary gland, Spleen
Metastatic prostatic adenocarcinoma
• Hrebinko R1, Taylor SR, Bahnson RR. Carcinoma of prostate metastatic to parotid gland. Urology. 1993 Mar;41(3):272-3.
• Simpson RH, Skálová A. Metastatic carcinoma of the prostate presenting as parotid tumour. Histopathology. 1997 Jan;30(1):70-4.
• Hélissey, C; Rouanne, M; Arnaud, F; Le Moulec, S. Parotid gland metastasis from prostate cancer. Anti-Cancer Drugs: March 2015 - Volume 26 - Issue 3 - p 367–370.
• Is docetaxel still the best treatment option?
• Important clinical question to answer- any neuroendocrine differentiation
Case 2
Female, 84 years
Painful lump left parotid
Scanned slide
Carcinoma ex-pleomorphic adenoma
Incidence
4% of salivary neoplasms, 12% of
salivary malignancies but only 1% of
intraoral salivary gland or minor salivary gland
neoplasms
5% of parotid tumors but 18% of malignant
parotid tumors
Associated with pleomorphic
adenomas: 2% risk of malignant
transformation if present < 5 years,
10% risk if 15 years
Clinically, have sudden increase in
growth, pain or facial paralysis, facial tingling, trismus
A 48-year-old woman with a carcinoma ex pleomorphic adenoma (case 1).
H. Kato et al. AJNR Am J Neuroradiol 2008;29:865-867
©2008 by American Society of Neuroradiology
A 76-year-old man with a carcinoma ex pleomorphic adenoma (case 2).
H. Kato et al. AJNR Am J Neuroradiol 2008;29:865-867
©2008 by American Society of Neuroradiology
a Ca ex PA demonstrating the co-existence of PA (left) and carcinoma (right) components (H&E, original magnification ×10). b Higher magnification of the PA area in a composed of glands with myoepithelial cells radiating out in a myxoid stroma (H&E, original magnification ×40). c Higher magnification of the carcinoma area in a composed of a poorly-differentiated adenocarcinoma with scanty glandular formation, marked nuclear pleomorphism and atypical mitosis (H&E, original magnification ×40)
Incidence of detection by FNA
Zbären et al reported that 44% (7 of 16) Ca ex PA cases showed malignant cells at FNAC
Zbären P, Zbären S, Caversaccio MD, Stauffer E. Carcinoma ex pleomorphic adenoma: diagnostic difficulty and outcome. OtolaryngolHead Neck Surg. 2008;138:601–605.
Nouraei et al noted that 29% (4 of 14) of the cancers were positive for malignancy by FNAC.
Nouraei SA, Hope KL, Kelly CG, et al. Carcinoma ex benign pleomorphic adenoma of the parotid gland. Plast ReconstrSurg. 2005;116:1206–1213.
Carcinoma ex-pleomorphic adenoma
Because the incidence of malignancy is correlated with the duration of pleomorphic adenoma, the risk of developing malignancy is only about 1.5% for a duration of <5 years but increases to 9.5% for a duration of >15 years.
Carcinoma ex pleomorphic adenoma is an infrequent aggressive malignancy that is believed to evolve from a pre-existing benign adenoma. It accounts for 3.6% (range, 0.9%–14%) of all salivary neoplasms and for 11.7% (range, 2.8%–42.4%) of salivary malignancies.
Prognosis of Ca ex-PA
Loco-regional recurrence is considered to be a major prognostic factor for patients with Ca ex PA. Olsen et al reported local recurrence in 23% of patients and regional recurrence in 18% of patients with Ca ex PA.
The prognosis after detection of progression or recurrence is poor, with a median survival of less than 1 year. Olsen et al noted that all disease specific deaths occurred within 6 years after the initial operation.
Olsen KD, Lewis JE. Carcinoma ex pleomorphic adenoma: a clinicopathological review. Head Neck. 2001;23:705–712.
Prognosis of Ca ex-PA
Olsen et al noted a 5 year disease-specific survival rate of 37% in 73 patients with the cancer
Nouraei et al reported 44% survival rates in 28 patients with the cancer
Zbären et al noted a higher survival rate of 75% in their series of 24 patients
Luers et al reported a survival rate of 60% in 22 patients with the cancer
The higher survival rate noted by Zbären et al may due to the higher proportion of intra-capsular Ca exPA
Molecular features
Molecular studies have revealed that the development of Ca ex PA follows a multi-step model of carcinogenesis
progressive loss of heterozygosity at chromosomal arms 8q, then 12q and finally 17p
There are specific candidate genes in these regions that are associated with particular stages in the progression of Ca ex PA
In addition, many genes which regulate tumour suppression, cell cycle control, growth factors and cell–cell adhesion play a role in the development and progression of Ca ex PA
Joyce Antony, Vinod Gopalan, Robert A. Smith and Alfred K. Y. Lam. Carcinoma ex Pleomorphic Adenoma: A Comprehensive Review of Clinical, Pathological and Molecular Data. Head and Neck Pathol (2012) 6:1–9
Prognostic factors
Stage, extent of invasion beyond the capsule (< 8 mm is associated with benign behavior)
Histologic type and grade of carcinoma, proliferation index, proportion of carcinoma
Extent of invasion, vascular invasion, atypical mitoses
Pathological stage, tumor size, proliferation index
Clinician reaction to SfM
Clinicians may regard even a malignant diagnosis as insufficient till specific type
(primary vs metastatic) is confirmed
Sometimes a suspicious diagnosis is sufficient for clinical management
Comments
RCPATH ENDORSES THE PARIS AND MILAN TERMINOLOGIES
CLINICAL SAFETY NET TO AVOID OVERTREATMENT
PRESSURE BY CLINICIANS AT MDM TO UPGRADE SFM TO MALIGNANT
SFM AT ROSE- HOLDING CATEGORY, ALLOWING PROVISIONAL DIAGNOSIS AND FEEDBACK TO RADIOLOGISTS AND TO CLINICIANS
NO ROSE NO FNA SERVICE
SAFE HAVEN- SOME STUDIES SHOW HIGHER PPV FOR SFM THAN MALIGNANT
TRAINEES- LEARN SALIVARY GLAND HISTOPATHOLOGY ALONGSIDE
ANCILLARY TESTS –GREAT IMPACT ON UPGRADING TO MALIGNANT NAMED PRIMARIES AND IN ASCERTAINING THE SITES OF METASTATIC CARCINOMA
Summary:
Suspicious for malignancy (SfM)
You believe that the aspirate is malignant but wish you had more cells with diagnostic features to be sure
Quantitative factor mainly
Not so much about a particular number of cells, rather about the presence of adequate diagnostic criteria in appropriate clinical context
Decision for SfM vs Malignant based on clinical context and experience of pathologist
ROSE and collection of adequate material may help in upgrading to Malignant category
References
• Rossi ED, Faquin WC, Baloch Z, Barkan GA, Foschini MP, Pusztaszeri M, et al. The Milan system for reporting salivary gland cytopathology: analysis and suggestions of initial survey. Cancer Cytopathol. 2017;125(10):757–66. https://doi.org/10.1002/cncy.21898.
• Contucci AM, Corina L, Sergi B, Fadda G, Paludetti G. Correlation between fine needle aspiration biopsy and histologic findings in parotid masses. Personal experience. Acta Otorhinolaryngol Ital. 2003;23(4):314–8.
• Griffith CC, Pai RK, Schneider F, Duvvuri U, Ferris RL, Johnson JT, Seethala RR. Salivary gland tumor fine needle aspiration cytology. A proposal for a risk stratification classification. Am J Clin Pathol. 2015;143(6):839–53.
• Hughes JH, Volk EE, Wilbur DC, Cytopathology Resource Committee, College of American Pathologists. Pitfalls in salivary gland fine needle aspiration cytology: lessons from the college of American pathologists interlaboratory comparison program in nongynaecologic cytology. Arch Pathol Lab Med. 2005;129(1):26–31.
• Jain R, Gupta R, Kudesia M, Singh S. Fine needle aspiration cytology in diagnosis of salivary gland lesions: a study with histologic comparison. Cytojournal. 2013;10:5.
• Mairembam P, Jay A, Beale T, Morley S, Vaz F, Kalavrezos N, Kocjan G. Salivary gland FNA cytology: role as a triage tool and an approach to pitfalls in cytomorphology. Cytopathology. 2016;27(2):91–6.
• Rossi ED, Wong LQ, Bizzarro T, Petrone G, Mule A, Fadda G, Baloch ZM. The impact of fine needle aspiration cytology in the management of salivary gland lesions: institutional experi- ences leading to a risk based classification scheme. Cancer Cytopathol. 2016;124(6):388–96.
• Brennan PA, Davies B, Poller D, Mead Z, Bayne D, Puxeddu R, Oeppen RS. Fine needle aspiration cytology (FNAC) of salivary gland tumours: repeat aspiration provides further information in cases with an unclear initial cytological diagnosis. Br J Oral Maxillofac Surg. 2010;48(1):26–9.
• Wei S, Layfield LJ, LiVolsi VA, Montone KT, Baloch ZW. Reporting of fine needle aspira- tion (FNA) specimens of salivary gland lesions: a comprehensive review. Diagn Cytopathol. 2017;45(9):820–7.
• Colella G, Cannavale R, Flamminio F, Foschini MP. Fine-needle aspiration cytology of sali- vary gland lesions: a systematic review. J Oral Maxillofac Surg. 2010;68(9):2146–53.
• Tyagi R, Dey P. Diagnostic problems of salivary gland tumors. Diagn Cytopathol. 2015;43(6):495–509.
Case history & ROSE findings
• 12 year old boy with a lump in the parotid gland
• USG FNA yielded a haemorrhagic mucoid aspirate on a single pass only
Case history & ROSE findings
• 12 year old boy with a lump in the parotid gland ?duration
• USG FNA yielded a haemorrhagic mucoid aspirate on single pass
• ROSE: SfM favour mucoepidermoid carcinoma
• Intradepartmental consensus meeting (Dr G Dixon): Malignant, favoursecretory carcinoma
• Insufficient material on cell block for ancillary tests
• Excision of nodule in the accessory lobe of the parotid
S100
GCDFP15
Histology
• S100 and GCDFP positive
• DOG1 negative
• Genetics (FISH) demonstrated t(12;15)(q13;q25) translocation, a fusion of the ETV6 and NTRK3 gene
• Features confirm secretory carcinoma